uniQure N. V. is a pioneering gene therapy company dedicated to discovering and developing therapeutic solutions for individuals afflicted with severe genetic and other debilitating illnesses. Its flagship program, Etranacogene dezaparvovec (AMT-061), is currently in a pivotal Phase III HOPE-B clinical trial for treating hemophilia B.